Targeting nucleocytoplasmic transport in cancer therapy

Oncotarget

Volumn 5, Issue 1, 2014, Pages 11-28

  Hill, Richard ^a   Cautain, Bastien ^b   De Pedro, Nuria ^b   Link, Wolfgang ^a  

^a UNIVERSITY OF ALGARVE   (Portugal)

^b Parque Tecnologico de Ciencias de la Salud   (Spain)

Author keywords

Anti cancer therapy; Cancer; Nuclear export; Nuclear import; Tumor suppressors

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; BORTEZOMIB; BRCA1 PROTEIN; CARFILZOMIB; CBS 9106; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KARYOPHERIN ALPHA; KOS 2464; NATURAL PRODUCT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEOPHOSMIN; NUCLEOPORIN; ONCOPROTEIN; PKF 050 638; PROTEASOME INHIBITOR; PROTEIN P27; PROTEIN P53; RAN PROTEIN; RETINOBLASTOMA PROTEIN; RETINOIC ACID; SELECTIVE INHIBITOR OF THE NUCLEAR EXPORT; SURVIVIN; TRANSCRIPTION FACTOR FOXO; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CELLULAR DISTRIBUTION; COLON CANCER; COMPETITIVE INHIBITION; DRUG TARGETING; HUMAN; NEOPLASM; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; NUCLEAR PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROTEIN TRANSPORT; REVIEW; UNSPECIFIED SIDE EFFECT; ACTIVE TRANSPORT; ANIMAL; METABOLISM; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84893870810     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1457     Document Type: Review

References (160)

1. Zanella F, Dos Santos NR, Link W. Moving to the core: spatiotemporal analysis of Forkhead box O (FOXO) and nuclear factor-kappaB (NF-kappaB) nuclear translocation. Traffic 2013; 14:247-58.
2. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 8:1021-32.
3. Hung MC, Link W. Protein localization in disease and therapy. J Cell Sci 2011; 15: 3381-92.
4. Cronshaw JM, Krutchinsky AN, Zhang W, Chait BT, Matunis MJ. Proteomic analysis of the mammalian nuclear pore complex. J Cell Biol 2002; 2: 915-27.
5. Kutay U, Guttinger S. Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol 2005; 15: 121-4.
6. Xu S, Powers MA. Nuclear pore proteins and cancer. Semin Cell Dev Biol 2009; 20: 620-30.
7. Ren Y, Seo HS, Blobel G, Hoelz A. Structural and functional analysis of the interaction between the nucleoporin Nup98 and the mRNA export factor Rae1. Proc Natl Acad Sci U S A 2010; 8: 10406-11.
8. Chin K, Devries S, Fridlyand J, Spellman P.T, Roydasgupta R, KuoW.L, Lapuk A, Neve R.M, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z.et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529-41.
9. Wong RW, Blobel G. Cohesin subunit SMC1 associates with mitotic microtubules at the spindle pole. Proc Natl Acad Sci U S A 2008; 7: 15441-5.
10. Moore D.J, Zienkiewicz, J, Kendall P.L, Liu D, Liu X, Veach R.A, Collins R.D, Hawiger J.In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes. PLoS One 2010; 5: e13235.
11. Nakamura T, Largaespada D.A, Lee M.P, Johnson L.A, Ohyashiki K, Toyama K, Chen S.J, Willman C.L, Chen I.M, Feinberg A.P, Jenkins N.A, Copeland N.G, Shaughnessy J.D Jr. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t7;11.p15;p15. in human myeloid leukaemia. Nat Genet 1996; 12: 154-8.
12. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude G.F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 6: 29-33.
13. Martinez N, Alonso A, Moragues MD, Ponton J, Schneider J. The nuclear pore complex protein Nup88 is overexpressed in tumor cells. Cancer Res 1999; 1: 5408-11.
14. Gould VE, Orucevic A, Zentgraf H, Gattuso P, Martinez N, Alonso A. Nup88 karyoporin. in human malignant neoplasms and dysplasias: correlations of immunostaining of tissue sections, cytologic smears, and immunoblot analysis. Hum Pathol 2002; 33: 536-44.
15. Agudo D, Gomez-Esquer F, Martinez-Arribas F, Nunez-Villar MJ, Pollan M, Schneider J. Nup88 mRNA overexpression is associated with high aggressiveness of breast cancer. Int J Cancer 2004; 1: 717-20.
16. Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, et al. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 2006; 12: 3950-60.
17. Kau TR, Silver PA. Nuclear transport as a target for cell growth. Drug Discov Today 2003; 15: 78-85.
18. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 2008; 15: 1733-43.
19. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2009; 32: E315.
20. Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun Y.J. Tang L.N. Zheng,S.E. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009; 21: 229-35.
21. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009; 65: 153-9.
22. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009; 15: 1829-40.
23. Kim IS, Kim DH, Han SM, Chin MU, Nam HJ, Cho HP. Truncated form of importin alpha identified in breast cancer cell inhibits nuclear import of p53. J Biol Chem 2000; 275: 23139-45.
24. Behrens P, Brinkmann U, Fogt F, Wernert N, Wellmann A. Implication of the proliferation and apoptosis associated CSE1L/CAS gene for breast cancer development. Anticancer Res 2001; 21: 2413-7.
25. Wellmann A, Flemming P, Behrens P, Wuppermann K, Lang H, Oldhafer K, Pastan I, Brinkmann U. High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression. Int J Mol Med 2001; 7: 489-94.
26. Brinkmann U, Gallo M, Polymeropoulos MH, Pastan I. The human CAS cellular apoptosis susceptibility. gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines. Genome Res 1996; 6: 187-94.
27. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004; 4: 106-17.
28. Levine AJ, Greenbaum B. The maintenance of epigenetic states by p53: the guardian of the epigenome. Oncotarget 2012; 3: 1503-4.
29. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 5: 49-53.
30. Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene 2000; 13: 232-40.
31. Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J. p53 cellular localization and function in neuroblastoma: evidence for defective G1. arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol 2001; 158: 2067-77.
32. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong H.C, Fu Y. Weng Z. Liu J. Zhao X.D. Chew J.L. Lee Y.L. Kuznetsov V.A. Sung W.K. Miller L.D. Lim B. Liu E.T. Yu Q. Ng H.H. Ruan Y. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006 13: 207-19.
33. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003; 12: 1972-5.
34. Pei D, Zhang Y, Zheng J. Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 2012; 3: 228-35.
35. Corvi R, Savelyeva L, Breit S, Wenzel A, Handgretinger R, Barak J, Oren M, Amler L, Schwab M. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 1995; 16: 1081-6.
36. Moll UM, LaQuaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A 1995; 9: 4407-11.
37. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003; 112: 29-40.
38. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 6: 844-8.
39. Ronca F, Yee KS, Yu VC. Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuroblastoma cells by modulating nuclear import of p53. J Biol Chem 1999; 18: 18128-34.
40. Steelman LS, Martelli AM, Nicoletti F, McCubrey JA. Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. Oncotarget 2011; 2: 109-12.
41. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9: 862-73.
42. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7: 847-59.
43. Zanella F, Link W, Carnero A. Understanding FOXO, new views on old transcription factors. Curr Cancer Drug Targets 2010; 10: 135-46.
44. Putker M, Madl T, Vos HR, de RH, Visscher M, van den Berg MC, Kaplan M, Korswagen H.C, Boelens R, Vermeulen M, Burgering B.M, Dansen T.B. Redox-dependent control of FOXO/DAF-16 by transportin-1. Mol Cell 2013; 21: 730-42.
45. Calnan DR, Brunet A. The FoxO code. Oncogene 2008; 7: 2276-88.
46. Yang H, Zhao R, Yang HY, Lee MH. Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene 2005; 10: 1924-35.
47. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 2009; 10: 1814-9.
48. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou,Y. Bao S, Hanada N, Saso H, Kobayashi R, Hung M.C. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 16: 225-37.
49. Hilmi C, Larribere L, Deckert M, Rocchi S, Giuliano S, Bille K, Ortonne J.P, Ballotti R, Bertolotto C. Involvement of FKHRL1 in melanoma cell survival and death. Pigment Cell Melanoma Res 2008; 21: 139-46.
50. Zanella F, Renner O, Garcia B, Callejas S, Dopazo A, Peregrina S, Link W. Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. Oncogene 2010; 20: 2973-82.
51. Cornforth AN, Davis JS, Khanifar E, Nastiuk KL, Krolewski JJ. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene 2008; 24: 4422-33.
52. Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget 2011; 2: 1314-21.
53. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012; 18: 892-901.
54. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998; 11: 1674-7.
55. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 15: 1501-12.
56. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002; 8: 1076-8.
57. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145-52.
58. Diersch S, Wenzel P, Szameitat M, Eser P, Paul MC, Seidler B. Efemp1 and p27Kip1. modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget 2013; 4: 277-88.
59. Rico-Bautista E, Wolf DA. Skipping Cancer: Small Molecule Inhibitors of SKP2-Mediated p27 Degradation. Chem Biol 2012; 21: 1497-8.
60. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12: 68-78.
61. Thakur S, Zhang HB, Peng Y, Le H, Carroll B, Ward T. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 1997; 17: 444-52.
62. Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, Lee WH. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem 1996; 20: 32863-8.
63. Schuchner S, Tembe V, Rodriguez JA, Henderson BR. Nuclear targeting and cell cycle regulatory function of human BARD1. J Biol Chem 2005; 11: 8855-61.
64. Thompson ME. BRCA1 16 years later: nuclear import and export processes. FEBS J 2010; 277: 3072-8.
65. Fabbro M, Rodriguez JA, Baer R, Henderson BR. BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem 2002; 14: 21315-24.
66. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor M.J, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 9: 123-34.
67. Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 2007; 168: 115-24.
68. Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008; 135: 367-75.
69. Fagotto F, Gluck U, Gumbiner BM. Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 1998; 12: 181-90.
70. Cong F, Varmus H. Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci U S A 2004; 2: 2882-7.
71. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a nuclear export function. Nature 2000; 31: 1009-12.
72. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 17: 235-7.
73. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of beta-catenin activity involves nuclear sequestration and nuclear export. EMBO Rep 2000; 1: 519-23.
74. Sikandar S, Dizon D, Shen X, Li Z, Besterman J, Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 2010; 1: 596-605.
75. Beg AA, Ruben SM, Scheinman RI, Haskill S, Rosen CA, Baldwin AS, Jr. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev 1992; 6: 1899-913.
76. Chen LF, Greene WC. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med (Berl) 2003; 81: 549-57.
77. Zanella F, Dos Santos NR, Link W. Moving to the Core: Spatiotemporal Analysis of Forkhead Box O (FOXO) and Nuclear Factor-kappaB (NF-kappaB) Nuclear Translocation. Traffic 2012; Dec 10:
78. Lindenboim L, Borner C, Stein R. Nuclear proteins acting on mitochondria. Biochim Biophys Acta 2011; 18: 584-96.
79. Lindenboim L, Blacher E, Borner C, Stein R. Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L). Cell Death Differ 2010; 17: 346-59.
80. Park KS, Han BG, Lee KH, Kim DS, Kim JM, Jeon H. Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells. Cancer Lett 2009; 18: 201-7.
81. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000; 11: 24451-7.
82. Szebeni A, Olson MO. Nucleolar protein B23 has molecular chaperone activities. Protein Sci 1999; 8: 905-12.
83. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005; 7: 823-30.
84. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007; 1: 874-85.
85. Nakagawa M, Kameoka Y, Suzuki R. Nucleophosmin in acute myelogenous leukemia. N Engl J Med 2005; 28: 1819-20.
86. Gavathiotis E, Reyna DE, Bellairs JA, Leshchiner ES, Walensky LD. Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol 2012; 8: 639-45.
87. Rodriguez JA, Span SW, Ferreira CG, Kruyt FA, Giaccone G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 2002; 15: 44-53.
88. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-27.
89. Colnaghi R, Connell CM, Barrett RM, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006; 3: 33450-6.
90. Knauer SK, Kramer OH, Knosel T, Engels K, Rodel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, Brieger J, Rodel C, Mann W, Petersen I, Heinzel T, Stauber RH. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007; 21: 207-16.
91. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
92. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
93. Yan S, Li Z, Thiele CJ. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo. Oncotarget 2013; 4: 433-45.
94. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 200; 8: 671-82.
95. Zhu L, Harlow E, Dynlacht BD. p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev 1995; 15: 1740-52.
96. Zamanian M, La Thangue NB. Transcriptional repression by the Rb-related protein p107. Mol Biol Cell 1993; 4: 389-96.
97. Mittnacht S. Control of pRB phosphorylation. Curr Opin Genet Dev 1998; 8: 21-7.
98. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF, Sherr CJ. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993; 7: 1559-71.
99. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000; 15: 3102-14.
100. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003; 1: 7056-61.
101. Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, Hardisson D, Sarrio D, Prat J, Cigudosa JC, Matias-Guiu X, Palacios J. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 2003; 4: 6115-8.
102. Faustino RS, Nelson TJ, Terzic A, Perez-Terzic C. Nuclear transport: target for therapy. Clin Pharmacol Ther 2007; 81: 880-6.
103. Zanella F, Rosado A, Garcia B, Carnero A, Link W. Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. BMC Cell Biol 2009; 10:14.
104. Martinez GS, Hernandez AI, Varela C, Rodriguez-Aristegui S, Lorenzo M, Rodriguez A, Lorenzo, M. Rodriguez A. Rivero V. Martin JI, Saluste CG, Ramos-Lima F, Cendon E, Cebrian D, Aguirre E, Gomez-Casero E, Albarran M, et al. Identification of ETP-46321, a potent and orally bioavailable PI3K alpha, delta inhibitor. Bioorg Med Chem Lett 2012; 15: 3460-6.
105. Link W, Oyarzabal J, Serelde BG, Albarran MI, Rabal O, Cebria A. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem 2009; 9: 28392-400.
106. Zanella F, Rosado A, Garcia B, Carnero A, Link W. Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening. Chembiochem 2008; 22: 2229-37.
107. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003; 4: 463-76.
108. Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, Difeo A. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest 2012; 2: 2637-51.
109. Roehrl MH, Kang S, Aramburu J, Wagner G, Rao A, Hogan PG. Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci U S A 2004; 18: 7554-9.
110. Kwon YJ, Genovesio A, Youl KN, Hi CK, Jung S, David-Watine B, Nehrbass U, Emans N. High-content classification of nucleocytoplasmic import or export inhibitors. J Biomol Screen 2007; 12: 621-7.
111. Davis JR, Kakar M, Lim CS. Controlling protein compartmentalization to overcome disease. Pharm Res 2007; 24: 17-27.
112. Chahine MN, Pierce GN. Therapeutic targeting of nuclear protein import in pathological cell conditions. Pharmacol Rev 2009; 61: 358-72.
113. Ambrus G, Whitby LR, Singer EL, Trott O, Choi E, Olson AJ. Small molecule peptidomimetic inhibitors of importin alpha/beta mediated nuclear transport. Bioorg Med Chem 2010; 1: 7611-20.
114. Gasiorowski JZ, Dean DA. Mechanisms of nuclear transport and interventions. Adv Drug Deliv Rev 2003; 16: 703-16.
115. Yoneda Y, Imamoto-Sonobe N, Yamaizumi M, Uchida T. Reversible inhibition of protein import into the nucleus by wheat germ agglutinin injected into cultured cells. Exp Cell Res 1987; 173: 586-95.
116. Hintersteiner M, Ambrus G, Bednenko J, Schmied M, Knox AJ, Meisner NC, Gstach H, Seifert JM, Singer EL, Gerace L, Auer M. Identification of a small molecule inhibitor of importin beta mediated nuclear import by confocal on-bead screening of tagged one-bead one-compound libraries. ACS Chem Biol 2010; 15: 967-79.
117. Soderholm JF, Bird SL, Kalab P, Sampathkumar Y, Hasegawa K, Uehara-Bingen M. Importazole, a small molecule inhibitor of the transport receptor importin-beta. ACS Chem Biol 2011; 15: 700-8.
118. Torgerson TR, Colosia AD, Donahue JP, Lin YZ, Hawiger J. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol 1998; 1: 6084-92.
119. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995; 16: 14255-8.
120. Kosugi S, Hasebe M, Entani T, Takayama S, Tomita M, Yanagawa H. Design of peptide inhibitors for the importin alpha/beta nuclear import pathway by activity-based profiling. Chem Biol 2008; 22: 940-9.
121. Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997; 19: 1041-50.
122. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horinouchi S. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 1999; 3: 9112-7.
123. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996; 74: 648-9.
124. Zanella F, Rosado A, Blanco F, Henderson BR, Carnero A, Link W. An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. Assay Drug Dev Technol 2007; 5: 333-41.
125. Zanella F, Lorens JB, Link W. High content screening: seeing is believing. Trends Biotechnol 2010; 28: 237-45.
126. Hayakawa Y, Sohda KY, Shin-Ya K, Hidaka T, Seto H. Anguinomycins C and D, new antitumor antibiotics with selective cytotoxicity against transformed cells. J Antibiot Tokyo. 1995; 48: 954-61.
127. Bonazzi S, Eidam O, Guttinger S, Wach JY, Zemp I, Kutay U, Gademann K. Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. J Am Chem Soc 2010; 3: 1432-42.
128. Koster M, Lykke-Andersen S, Elnakady YA, Gerth K, Washausen P, Hofle G, Sasse F, Kjems J, Hauser H. Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp Cell Res 2003; 10: 321-31.
129. Tamura S, Shiomi A, Kaneko M, Ye Y, Yoshida M, Yoshikawa M, Kimura T, Kobayashi M, Murakami N. New Rev-export inhibitor from Alpinia galanga and structure-activity relationship. Bioorg Med Chem Lett 2009; 1: 2555-7.
130. Murakami N, Ye Y, Kawanishi M, Aoki S, Kudo N, Yoshida M, Nakayama EE, Shioda T, Kobayashi M. New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg Med Chem Lett 2002; 21: 2807-10.
131. Tamura S, Kaneko M, Shiomi A, Yang GM, Yamaura T, Murakami N. Unprecedented NES non-antagonistic inhibitor for nuclear export of Rev from Sida cordifolia. Bioorg Med Chem Lett 2010; 15: 1837-9.
132. Cautain B, de Pedro N, Murillo G, V, Munoz de EM, Gonzalez M, V, Tormo JR, Link W. High-Content Screening of Natural Products Reveals Novel Nuclear Export Inhibitors. J Biomol Screen 2013; 17.
133. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De CE. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A 2002; 29: 14440-5.
134. Van NT, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 2008; 1: 9487-97.
135. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB, Murli S. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009; 15: 510-7.
136. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011; 6: 3922-31.
137. Mao L, Yang Y. Targeting the nuclear transport machinery by rational drug design. Curr Pharm Des 2013; 19: 2318-25.
138. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007; 13: 1001-9.
139. Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 2007; 15: 7264-70.
140. Blagosklonny MV. Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget 2012; 3: 1711-24.
141. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004; 24: 4395-406.
142. Fabbro M, Henderson BR. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003; 15: 59-69.
143. Rodriguez JA, Schuchner S, Au WW, Fabbro M, Henderson BR. Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1. Oncogene 2004; 11: 1809-20.
144. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-10.
145. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res 2006; 15: 3044-50.
146. Besson A, Assoian RK, Roberts JM. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nat Rev Cancer 2004; 4: 948-55.
147. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-67.
148. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG, Ito Y. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 2005; 1: 7743-50.
149. Craig E, Zhang ZK, Davies KP, Kalpana GV. A masked NES in INI1/hSNF5 mediates hCRM1-dependent nuclear export: implications for tumorigenesis. EMBO J 2002; 15: 31-42.
150. Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 2009; 9: 810-20.
151. Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci 2008; 1: 249-53.
152. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228-34.
153. Welcker M, Larimore EA, Frappier L, Clurman BE. Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol 2011; 31: 1214-24.
154. Rosado A, Zanella F, Garcia B, Carnero A, Link W. A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling. PLoS One 2008; 3:e1823.
155. Olsen LS, Hjarnaa PJ, Latini S, Holm PK, Larsson R, Bramm E. Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int J Cancer 2004; 20: 198-205.
156. Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005; 27: 20589-95.
157. Xu GW, Mawji IA, Macrae CJ, Koch CA, Datti A, Wrana JL, Dennis J.W, Schimmer A.D. A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization. Apoptosis 2008; 13: 413-22.
158. Wach JY, Guttinger S, Kutay U, Gademann K. The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg Med Chem Lett 2010; 1: 2843-6.
159. Tamura S, Tsuji K, Yongzhen P, Ohnishi-Kameyama M, Murakami N. Six new acylated anthocyanins from red radish Raphanus sativus. Chem Pharm Bull (Tokyo) 2010; 58: 1259-62.
160. Hilliard M, Frohnert C, Spillner C, Marcone S, Nath A, Lampe T, Fitzgerald D. J, Kehlenbach R.H. The anti-inflammatory prostaglandin 15-deoxy-delta(12,14)-PGJ2 inhibits CRM1-dependent nuclear protein export. J Biol Chem 2010; 16: 22202-10.